Journey Medical Corp (DERM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $122.24M
Last updated: Nov 17, 2026 at 11:04 AM ET
Journey Medical Corp (DERM) Stock Forecast
Analysts expect Journey Medical (DERM) to earn -$0.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $77.50M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 50.0%.
- Fiscal year ending Dec 31, 2026
- -$0.13
- EPS consensus, revenue $77.50M
- Fiscal year ending Dec 31, 2027
- $0.44
- EPS consensus, revenue $116.25M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.29 to $0.02 | 4 | $77.50M | $75.10M to $82.37M | 4 |
| Dec 31, 2027 | $0.44 | $0.15 to $0.72 | 4 | $116.25M | $103.50M to $134.29M | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.00 | -$0.12 to $0.08 | 6 | $22.02M | $18.82M to $27.52M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a profit of $0.07 to a loss.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.13 | -$0.13 | -$0.04 | -$0.04 | $0.07 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.44 | $0.44 | $0.68 | $0.68 | $1.04 | -57.3% |
Frequently Asked Questions About DERM
What is the DERM stock forecast?
Consensus analyst estimates put Journey Medical's EPS at -$0.13 for the fiscal year ending Dec 31, 2026, on revenue of $77.50M. The consensus rating from 4 analysts is Buy.
How do analysts rate DERM stock?
Of 4 analysts covering Journey Medical, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DERM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.13, with estimates from -$0.29 to $0.02 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.44, with estimates from $0.15 to $0.72 from 4 analysts.
What revenue do analysts expect from Journey Medical next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $77.50M, with estimates from $75.10M to $82.37M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $116.25M, with estimates from $103.50M to $134.29M.
How many analysts cover DERM?
4 analysts rate Journey Medical stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DERM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors